ACE in the hole?
One year on, Professor Peter Rossing revisits controversies over the impact on COVID-19 outcomes of RAS-blocking agents and other therapies used by people with diabetes
One year on, Professor Peter Rossing revisits controversies over the impact on COVID-19 outcomes of RAS-blocking agents and other therapies used by people with diabetes